Cargando…

Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study

BACKGROUND: The value of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in early breast cancer (BC) is unclear. We explored the correlation between the LCR and survival of patients with early BC and established effective LCR-based prognostic signatures for predicting prognosis. METHODS: In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Zhang, Yu-Ling, Jiang, Chang, Duan, Fang-Fang, Yuan, Zhong-Yu, Huang, Jia-Jia, Bi, Xi-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289276/
https://www.ncbi.nlm.nih.gov/pubmed/35860229
http://dx.doi.org/10.2147/JIR.S364284
_version_ 1784748629318172672
author Wang, Li
Zhang, Yu-Ling
Jiang, Chang
Duan, Fang-Fang
Yuan, Zhong-Yu
Huang, Jia-Jia
Bi, Xi-Wen
author_facet Wang, Li
Zhang, Yu-Ling
Jiang, Chang
Duan, Fang-Fang
Yuan, Zhong-Yu
Huang, Jia-Jia
Bi, Xi-Wen
author_sort Wang, Li
collection PubMed
description BACKGROUND: The value of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in early breast cancer (BC) is unclear. We explored the correlation between the LCR and survival of patients with early BC and established effective LCR-based prognostic signatures for predicting prognosis. METHODS: In this retrospective study, we randomized 623 patients with early-stage BC diagnosed in December 2010 to October 2012 at the Sun Yat-sen University Cancer Center to training and verification datasets. The median follow-up of all patients was 109 months. The survival differences were calculated by Kaplan–Meier method using the Log rank test. For overall survival (OS) and disease-free survival (DFS), the independent factors in the training dataset were identified using univariate and multivariate Cox analyses, in which two-tailed P-values < 0.05 were considered statistically significant. Based on this, we respectively constructed novel signatures for survival prediction and validated the efficiency of signatures through the concordance index (C-index), calibration and receiver operating characteristic (ROC) curves in both datasets. RESULTS: The LCR, lymphatic vessel invasion (LVI), progesterone receptor (PR) status, and Ki67 index were independent prognostic factors of OS. And the LCR and LVI are associated to DFS too. High LCR was associated with better OS and DFS. We constructed the prediction signatures based on those independent prognostic factors and calculated the risk scores. Patients in the training dataset with higher risk scores had significantly worse prognosis (P < 0.001). The signature had excellent discrimination capacity, with an OS C-index of 0.785 [95% confidence interval (CI): 0.713–0.857] and 0.750 (95% CI: 0.669–0.832) in the training and verification datasets, respectively. The time–ROC curves also suggest accurate prediction by the signature. CONCLUSION: The LCR was a significant prognostic predictor of OS and DFS in early BC. The LCR-based prognostic signatures could be a useful tool for individualized therapeutic guidance.
format Online
Article
Text
id pubmed-9289276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92892762022-07-19 Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study Wang, Li Zhang, Yu-Ling Jiang, Chang Duan, Fang-Fang Yuan, Zhong-Yu Huang, Jia-Jia Bi, Xi-Wen J Inflamm Res Original Research BACKGROUND: The value of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in early breast cancer (BC) is unclear. We explored the correlation between the LCR and survival of patients with early BC and established effective LCR-based prognostic signatures for predicting prognosis. METHODS: In this retrospective study, we randomized 623 patients with early-stage BC diagnosed in December 2010 to October 2012 at the Sun Yat-sen University Cancer Center to training and verification datasets. The median follow-up of all patients was 109 months. The survival differences were calculated by Kaplan–Meier method using the Log rank test. For overall survival (OS) and disease-free survival (DFS), the independent factors in the training dataset were identified using univariate and multivariate Cox analyses, in which two-tailed P-values < 0.05 were considered statistically significant. Based on this, we respectively constructed novel signatures for survival prediction and validated the efficiency of signatures through the concordance index (C-index), calibration and receiver operating characteristic (ROC) curves in both datasets. RESULTS: The LCR, lymphatic vessel invasion (LVI), progesterone receptor (PR) status, and Ki67 index were independent prognostic factors of OS. And the LCR and LVI are associated to DFS too. High LCR was associated with better OS and DFS. We constructed the prediction signatures based on those independent prognostic factors and calculated the risk scores. Patients in the training dataset with higher risk scores had significantly worse prognosis (P < 0.001). The signature had excellent discrimination capacity, with an OS C-index of 0.785 [95% confidence interval (CI): 0.713–0.857] and 0.750 (95% CI: 0.669–0.832) in the training and verification datasets, respectively. The time–ROC curves also suggest accurate prediction by the signature. CONCLUSION: The LCR was a significant prognostic predictor of OS and DFS in early BC. The LCR-based prognostic signatures could be a useful tool for individualized therapeutic guidance. Dove 2022-07-13 /pmc/articles/PMC9289276/ /pubmed/35860229 http://dx.doi.org/10.2147/JIR.S364284 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Li
Zhang, Yu-Ling
Jiang, Chang
Duan, Fang-Fang
Yuan, Zhong-Yu
Huang, Jia-Jia
Bi, Xi-Wen
Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title_full Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title_fullStr Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title_full_unstemmed Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title_short Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
title_sort novel signatures based on the lymphocyte-to-c-reactive protein ratio predict the prognosis of patients with early breast cancer: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289276/
https://www.ncbi.nlm.nih.gov/pubmed/35860229
http://dx.doi.org/10.2147/JIR.S364284
work_keys_str_mv AT wangli novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT zhangyuling novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT jiangchang novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT duanfangfang novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT yuanzhongyu novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT huangjiajia novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy
AT bixiwen novelsignaturesbasedonthelymphocytetocreactiveproteinratiopredicttheprognosisofpatientswithearlybreastcanceraretrospectivestudy